Molecular and biologic markers of progression in monoclonal gammopathy of undetermined significance to multiple myeloma

References

• Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun M. Cancer statistics, 2009. CA Cancer J Clin 2009;59:225–249.
   PubMed Web of Science ®Google Scholar
• Kristinsson SY, Landgren O, Dickman PW, Derolf AR, Bjorkholm M. Patterns of survival in multiple myeloma: a population-based study of patients diagnosed in Sweden from 1973 to 2003. J Clin Oncol 2007;25:1993–1999.
   PubMed Web of Science ®Google Scholar
• Kumar SK, Rajkumar SV, Dispenzieri A, Improved survival in multiple myeloma and the impact of novel therapies. Blood 2008;111:2516–2520.
   PubMed Web of Science ®Google Scholar
• Kyle RA, Therneau TM, Rajkumar SV, Prevalence of monoclonal gammopathy of undetermined significance. N Engl J Med 2006;354:1362–1329.
   PubMed Web of Science ®Google Scholar
• Kyle RA, Rajkumar SV. Monoclonal gammopathy of undetermined significance. Br J Haematol 2006;134:573–589.
   PubMed Web of Science ®Google Scholar
• Kyle RA, Therneau TM, Rajkumar SV, A long-term study of prognosis in monoclonal gammopathy of undetermined significance. N Engl J Med 2002;346:564–569.
   PubMed Web of Science ®Google Scholar
• Landgren O, Gridley G, Turesson I, Risk of monoclonal gammopathy of undetermined significance (MGUS) and subsequent multiple myeloma among African American and white veterans in the United States. Blood 2006;107:904–906.
   PubMed Web of Science ®Google Scholar
• Bowden M, Crawford J, Cohen HJ, Noyama O. A comparative study of monoclonal gammopathies and immunoglobulin levels in Japanese and United States elderly. J Am Geriatr Soc 1993;41:11–14.
   PubMed Web of Science ®Google Scholar
• Parkin DM, Whelan SL, Ferlay J, Teppo L, Thomas DB. Cancer incidence in five continents, Vol. VIII. Lyon: IARC; 2002.
   Google Scholar
• Iwanaga M, Tagawa M, Tsukasaki K, Kamihira S, Tomonaga M. Prevalence of monoclonal gammopathy of undetermined significance: study of 52 802 persons in Nagasaki City, Japan. Mayo Clin Proc 2007;82:1474–1479.
   PubMed Web of Science ®Google Scholar
• Landgren O, Linet MS, McMaster ML, Gridley G, Hemminki K, Goldin LR. Familial characteristics of autoimmune and hematologic disorders in 8406 multiple myeloma patients: a population-based case–control study. Int J Cancer 2006;118:3095–3098.
   PubMed Web of Science ®Google Scholar
• Landgren O, Kristinsson SY, Goldin LR, Risk of plasma-cell and lymphoproliferative disorders among 14 621 first-degree relatives of 4458 patients with monoclonal gammopathy of undetermined significance (MGUS) in Sweden. Blood 2009;114:791–795.
   PubMed Web of Science ®Google Scholar
• Landgren O, Kyle RA, Pfeiffer RM, Monoclonal gammopathy of undetermined significance (MGUS) consistently precedes multiple myeloma: a prospective study. Blood 2009;113:5412–5417.
   PubMed Web of Science ®Google Scholar
• Weiss BM, Abadie J, Verma P, Howard RS, Kuehl WM. A monoclonal gammopathy precedes multiple myeloma in most patients. Blood 2009;113:5418–5422.
   PubMed Web of Science ®Google Scholar
• Kyle RA, Therneau TM, Rajkumar SV, Long-term follow-up of IgM monoclonal gammopathy of undetermined significance. Blood 2003;102:3759–3764.
   PubMed Web of Science ®Google Scholar
• Rajkumar SV, Kyle RA, Therneau TM, Serum free light chain ratio is an independent risk factor for progression in monoclonal gammopathy of undetermined significance. Blood 2005;106:812–817.
   PubMed Web of Science ®Google Scholar
• Dispenzieri A, Kyle RA, Katzmann JA, Immunoglobulin free light chain ratio is an independent risk factor for progression of smoldering (asymptomatic) multiple myeloma. Blood 2008;111:785–789.
   PubMed Web of Science ®Google Scholar
• Perez-Persona E, Vidriales MB, Mateo G, New criteria to identify risk of progression in monoclonal gammopathy of uncertain significance and smoldering multiple myeloma based on multiparameter flow cytometry analysis of bone marrow plasma cells. Blood 2007;110:2586–2592.
   PubMed Web of Science ®Google Scholar
• Chng WJ, Van Wier SA, Ahmann GJ, A validated FISH trisomy index demonstrates the hyperdiploid and nonhyperdiploid dichotomy in MGUS. Blood 2005;106:2156–2161.
   PubMed Web of Science ®Google Scholar
• Chiecchio L, Dagrada GP, Ibrahim AH, Timing of acquisition of deletion 13 in plasma cell dyscrasias is dependent on genetic context. Haematologica 2009;94:1708–1713.
   PubMed Web of Science ®Google Scholar
• Fonseca R, Debes-Marun CS, Picken EB, The recurrent IgH translocations are highly associated with nonhyperdiploid variant multiple myeloma. Blood 2003;102:2562–2567.
   PubMed Web of Science ®Google Scholar
• Debes-Marun CS, Dewald GW, Bryant S, Chromosome abnormalities clustering and its implications for pathogenesis and prognosis in myeloma. Leukemia 2003;17:427–436.
   PubMed Web of Science ®Google Scholar
• Smadja NV, Fruchart C, Isnard F, Chromosomal analysis in multiple myeloma: cytogenetic evidence of two different diseases. Leukemia 1998;12:960–969.
   PubMed Web of Science ®Google Scholar
• Saez B, Martin-Subero JI, Guillen-Grima F, Chromosomal abnormalities clustering in multiple myeloma reveals cytogenetic subgroups with nonrandom acquisition of chromosomal changes. Leukemia 2004;18:654–657.
   PubMed Web of Science ®Google Scholar
• Smadja NV, Leroux D, Soulier J, Further cytogenetic characterization of multiple myeloma confirms that 14q32 translocations are a very rare event in hyperdiploid cases. Genes Chromosomes Cancer 2003;38:234–239.
   PubMed Web of Science ®Google Scholar
• Kuehl WM, Bergsagel PL. Multiple myeloma: evolving genetic events and host interactions. Nat Rev Cancer 2002;2:175–187.
   PubMed Web of Science ®Google Scholar
• Avet-Loiseau H, Facon T, Grosbois B, Oncogenesis of multiple myeloma: 14q32 and 13q chromosomal abnormalities are not randomly distributed, but correlate with natural history, immunological features, and clinical presentation. Blood 2002;99:2185–2191.
   PubMed Web of Science ®Google Scholar
• Fonseca R, Bailey RJ, Ahmann GJ, Genomic abnormalities in monoclonal gammopathy of undetermined significance. Blood 2002;100:1417–1424.
   PubMed Web of Science ®Google Scholar
• Konigsberg R, Ackermann J, Kaufmann H, Deletions of chromosome 13q in monoclonal gammopathy of undetermined significance. Leukemia 2000;14:1975–1979.
   PubMed Web of Science ®Google Scholar
• Rasmussen T, Kuehl M, Lodahl M, Johnsen HE, Dahl IM. Possible roles for activating RAS mutations in the MGUS to MM transition and in the intramedullary to extramedullary transition in some plasma cell tumors. Blood 2005;105:317–323.
   PubMed Web of Science ®Google Scholar
• Bezieau S, Devilder MC, Avet-Loiseau H, High incidence of N and K-Ras activating mutations in multiple myeloma and primary plasma cell leukemia at diagnosis. Hum Mutat 2001;18:212–224.
   PubMed Web of Science ®Google Scholar
• Chng WJ, Gonzalez-Paz N, Price-Troska T, Clinical and biological significance of RAS mutations in multiple myeloma. Leukemia 2008;22:2280–2284.
   PubMed Web of Science ®Google Scholar
• Chesi M, Robbiani D, Sebag M, AID-dependent activation of a MYC transgene induces multiple myeloma in a conditional mouse model of post-germinal center malignancies. Cancer Cell 2008;13:167–180.
   PubMed Web of Science ®Google Scholar
• Zhan F, Barlogie B, Arzoumanian V, Gene-expression signature of benign monoclonal gammopathy evident in multiple myeloma is linked to good prognosis. Blood 2007;109:1692–1700.
   PubMed Web of Science ®Google Scholar
• Nevins JR, Potti A. Mining gene expression profiles: expression signatures as cancer phenotypes. Nat Rev Genet 2007;8:601–609.
   PubMed Web of Science ®Google Scholar
• Shaughnessy JD Jr. Global gene expression profiling in the study of multiple myeloma. Int J Hematol 2003;77:213–225.
   PubMed Web of Science ®Google Scholar
• Zhan F, Tian E, Bumm K, Smith R, Barlogie B, Shaughnessy J Jr. Gene expression profiling of human plasma cell differentiation and classification of multiple myeloma based on similarities to distinct stages of late-stage B-cell development. Blood 2003;101:1128–1140.
   PubMed Web of Science ®Google Scholar
• Shaughnessy JD Jr, Zhan F, Burington BE, A validated gene expression model of high-risk multiple myeloma is defined by deregulated expression of genes mapping to chromosome 1. Blood 2007;109:2276–2284.
   PubMed Web of Science ®Google Scholar
• Anguiano A, Tuchman SA, Acharya C, Gene expression profiles of tumor biology provide a novel approach to prognosis and may guide the selection of therapeutic targets in multiple myeloma. J Clin Oncol 2009;27:4197–4203.
   PubMed Web of Science ®Google Scholar
• Zhan F, Hardin J, Kordsmeier B, Global gene expression profiling of multiple myeloma, monoclonal gammopathy of undetermined significance, and normal bone marrow plasma cells. Blood 2002;99:1745–1757.
   PubMed Web of Science ®Google Scholar
• Ria R, Todoerti K, Berardi S, Gene expression profiling of bone marrow endothelial cells in patients with multiple myeloma. Clin Cancer Res 2009;15:5369–5378.
   PubMed Web of Science ®Google Scholar
• Lee RC, Feinbaum RL, Ambros V. The C. elegans heterochronic gene lin-4 encodes small RNAs with antisense complementarity to lin-14. Cell 1993;75:843–854.
   PubMed Web of Science ®Google Scholar
• Bartel DP. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell 2004;116:281–297.
   PubMed Web of Science ®Google Scholar
• Zhang B, Pan X, Cobb GP, Anderson TA. microRNAs as oncogenes and tumor suppressors. Dev Biol 2007;302:1–12.
   PubMed Web of Science ®Google Scholar
• Chan JA, Krichevsky AM, Kosik KS. MicroRNA-21 is an antiapoptotic factor in human glioblastoma cells. Cancer Res 2005;65:6029–6033.
   PubMed Web of Science ®Google Scholar
• Pichiorri F, Suh SS, Ladetto M, MicroRNAs regulate critical genes associated with multiple myeloma pathogenesis. Proc Natl Acad Sci USA 2008;105:12885–12890.
   PubMed Web of Science ®Google Scholar
• Chen CZ, Li L, Lodish HF, Bartel DP. MicroRNAs modulate hematopoietic lineage differentiation. Science 2004;303:83–86.
   PubMed Web of Science ®Google Scholar
• Jones PA, Baylin SB. The fundamental role of epigenetic events in cancer. Nat Rev Genet 2002;3:415–428.
   PubMed Web of Science ®Google Scholar
• Takahashi T, Shivapurkar N, Reddy J, DNA methylation profiles of lymphoid and hematopoietic malignancies. Clin Cancer Res 2004;10:2928–2935.
   PubMed Web of Science ®Google Scholar
• Chim CS, Liang R, Tam CY, Kwong YL. Methylation of p15 and p16 genes in acute promyelocytic leukemia: potential diagnostic and prognostic significance. J Clin Oncol 2001;19:2033–2040.
   PubMed Web of Science ®Google Scholar
• Seidl S, Ackermann J, Kaufmann H, DNA-methylation analysis identifies the E-cadherin gene as a potential marker of disease progression in patients with monoclonal gammopathies. Cancer 2004;100:2598–2606.
   PubMed Web of Science ®Google Scholar
• Martin P, Garcia-Cosio M, Santon A, Bellas C. Aberrant gene promoter methylation in plasma cell dyscrasias. Exp Mol Pathol 2008;84:256–261.
   PubMed Web of Science ®Google Scholar
• Stanganelli C, Arbelbide J, Fantl DB, Corrado C, Slavutsky I. DNA methylation analysis of tumor suppressor genes in monoclonal gammopathy of undetermined significance. Ann Hematol 2010;89:191–199.
   PubMed Web of Science ®Google Scholar
• Bredella MA, Steinbach L, Caputo G, Segall G, Hawkins R. Value of FDG PET in the assessment of patients with multiple myeloma. AJR Am J Roentgenol 2005;184:1199–1204.
   PubMed Web of Science ®Google Scholar
• Adam Z, Bolcak K, Stanicek J, Fluorodeoxyglucose positron emission tomography in multiple myeloma, solitary plasmocytoma and monoclonal gammapathy of unknown significance. Neoplasma 2007;54:536–540.
   PubMed Web of Science ®Google Scholar
• Grant FD, Fahey FH, Packard AB, Skeletal PET with 18F-fluoride: applying new technology to an old tracer. J Nucl Med 2008;49:68–78.
   PubMed Web of Science ®Google Scholar
• Even-Sapir E, Metser U, Flusser G, Assessment of malignant skeletal disease: initial experience with 18F-fluoride PET/CT and comparison between 18F-fluoride PET and 18F-fluoride PET/CT. J Nucl Med 2004;45:272–278.
   PubMed Web of Science ®Google Scholar
• Folkman J, Watson K, Ingber D, Hanahan D. Induction of angiogenesis during the transition from hyperplasia to neoplasia. Nature 1989;339:58–61.
   PubMed Web of Science ®Google Scholar
• Moehler TM, Ho AD, Goldschmidt H, Barlogie B. Angiogenesis in hematologic malignancies. Crit Rev Oncol Hematol 2003;45:227–244.
   PubMed Web of Science ®Google Scholar
• Munshi NC, Wilson C. Increased bone marrow microvessel density in newly diagnosed multiple myeloma carries a poor prognosis. Semin Oncol 2001;28:565–569.
   PubMed Web of Science ®Google Scholar
• Hillengass J, Zechmann C, Bauerle T, Dynamic contrast-enhanced magnetic resonance imaging identifies a subgroup of patients with asymptomatic monoclonal plasma cell disease and pathologic microcirculation. Clin Cancer Res 2009;15:3118–3125.
   PubMed Web of Science ®Google Scholar
• Ley TJ, Mardis ER, Ding L, DNA sequencing of a cytogenetically normal acute myeloid leukaemia genome. Nature 2008;456:66–72.
   PubMed Web of Science ®Google Scholar
• Mardis ER, Ding L, Dooling DJ, Recurring mutations found by sequencing an acute myeloid leukemia genome. N Engl J Med 2009;361:1058–1066.
   PubMed Web of Science ®Google Scholar
• Pleasance ED, Cheetham RK, Stephens PJ, A comprehensive catalogue of somatic mutations from a human cancer genome. Nature 2010;463:191–196.
   PubMed Web of Science ®Google Scholar